Published in final edited form as:

Pharmacol Biochem Behav. 2008 April ; 89(2): 145–149. doi:10.1016/j.pbb.2007.12.003.

MEASURING NICOTINE INTAKE AMONG HIGHLY DEPENDENT ADOLESCENT SMOKERS: COMPARABILITY OF SALIVA AND PLASMA COTININE CONCENTRATIONS

Craig S. Parzynski, BA, Maria Jaszyna-Gasior, MD, PhD, Frederick H. Franken, BS, and Eric T. Moolchan, MD

DHHS/NIH/NIDA-IRP, Baltimore, Maryland

Abstract

Cotinine is the most common biomarker used to assess nicotine exposure and abstinence. It can be measured in various matrices including saliva, plasma, and urine. Previous research with adults has shown high correlations between saliva and plasma cotinine concentrations. However, research has not examined this relationship in adolescents. Additionally, variability in saliva flow and metabolism across gender, ethnicity, and age may impact the relationship between saliva and plasma cotinine concentration. Our aim was to examine the relationship between saliva and plasma cotinine concentration in a group of nicotine-dependent adolescent smokers. Additionally, we examined these correlations across gender, ethnicity and age. The sample consisted of 66 adolescent smokers (age 15.1 ± 1.3 , 63.6% girls, 66.7% European American, CPD 18.3 ± 8.5 , FTND 7.1 ± 1.3). Saliva and plasma specimens were collected before the treatment phase of a nicotine replacement therapy trial and analyzed. The relationship between saliva and plasma cotinine concentration was analyzed using Pearson's correlation coefficients. We performed a secondary analysis using multiple regression to compare correlations across race, gender and age. Results indicated a positive correlation between saliva cotinine and plasma cotinine concentration ($r = .84, p < .001$). Differences in correlations across age were significant ($t = 3.03, p < .01$). Differences across ethnicity approached significance ($t = -1.93, p = .058$). Future research should seek to further validate saliva-to-plasma cotinine concentration ratios in adolescents as well as characterize saliva-to-plasma concentration differences and their underlying mechanisms.

Introduction

Tobacco use kills 438,000 Americans each year and is the most preventable cause of death in the United States (CDC, 2005). More than 80% of these smokers will have started smoking before the age of 18 (USDHHS, 1994). Beginning in 1997, the adolescent smoking trend began to decline (CDC, 2006); however, recent data show that still approximately 3,900 adolescents between the ages of 12 and 17 try smoking everyday and more than 1,500 become daily smokers (SAMHSA, 2005). According to the National Center for Health Statistics, by grade twelve, 29% of boys and 23% of girls are current smokers with about half of them smoking on a frequent basis (20 days or more in the last 30 days) (NCHS, 2005). Thus, it is important to test and

Correspondence to: Eric T. Moolchan, MD, Teen Tobacco Addiction Treatment Research Clinic, National Institute on Drug Abuse Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, MD 21224, Tel: (410) 550-1846, Fax: (410) 550-1656, Email: emoolcha@intra.nida.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

implement prevention and treatment interventions that have the potential to mitigate tobacco dependence in adolescent populations.

Several studies have tested the efficacy of nicotine replacement therapies (NRT) (Hanson et al., 2003; Hurt et al., 2000; Moolchan et al., 2005) and cognitive behavioral therapy (Krishnan-Sarin et al., 2006; Stevens et al., 2005) in adolescent populations. In order to determine the success of such interventions, an efficient means of testing nicotine exposure and abstinence beyond subjective self reporting must be available. Self-reporting, particularly among adolescents, has been shown to be only moderately reliable (Dolcini et al., 2003); therefore, self-report combined with biological markers has a greater ability to accurately reflect smoking status and degree of tobacco exposure. Due to its relatively long half-life, cotinine concentration is often used as a marker of tobacco exposure and abstinence (Benowitz et al., 2002).

Cotinine, the primary metabolite of nicotine, can be assayed in various biological fluids including blood, saliva, urine, and semen (Bramer & Kallungal, 2003). It is estimated that an average of 70–80% of the nicotine absorbed by a smoker is metabolized to cotinine (Bramer & Kallungal, 2003). Cotinine testing provides a more accurate measure than exhaled air carbon monoxide, one of the most widely-used biomarkers in smoking research (Dolcini, et al., 2003; Patrick et al., 1994), and has proved to be advantageous in examining nicotine intake due to its ability to estimate tobacco smoke exposure over a longer time frame than CO monitoring.

Cotinine has most frequently been assayed in plasma samples. Plasma cotinine concentration is highly correlated with tobacco smoke exposure from both direct smoke inhalation via cigarette consumption and environmental exposure via secondhand smoke (Eskenazi et al., 1995; Godtfredsen et al., 2006; Simoni et al., 2006; St. Charles et al., 2006).

Despite the reliability of plasma samples, drawing blood often presents logistical problems in a research setting (Benowitz & Jacob, 1994). Taking blood specimens is invasive, can cause stress and discomfort in some participants, and is impractical or even unethical in some instances (Jarvis et al., 2003). This is particularly true in adolescent populations where parental consent, adolescent decision-making ability, confidentiality, and treatment issues are major barriers to clinical trials (Moolchan & Mermelstein, 2002). Therefore using the least invasive means of objectively assessing nicotine intake is advantageous in smoking cessation trials with adolescents.

The use of saliva provides an alternative. Salivary testing offers a cost-effective, convenient, non-invasive method for assessing cotinine levels that eliminates the discomfort of drawing blood (Jarvis et al., 2003). Beyond the logistical advantages, previous research in adult populations suggests that saliva and plasma cotinine levels correlate highly and has a similar terminal half-life in both matrices. Rose et al. (1993) found that in adult populations saliva and plasma cotinine were highly correlated ($r = 0.94$). More recently Jarvis et al. (2003) found a correlation between saliva and plasma cotinine of $r = 0.99$ with saliva cotinine concentrations 25% higher than plasma concentrations. This finding is consistent with the SRNT Subcommittee on Biochemical Verification (2002) that states saliva cotinine concentrations are on average 10 to 40% higher than plasma cotinine levels. This range in variability can be caused by the amount of salivary gland stimulation; cotinine concentrations are lower in stimulated samples compared to unstimulated samples (Schneider et al., 1997).

The benefits of saliva sampling for cotinine further increase the need for validation of this method in an adolescent population. The aim of the present study was to explore whether the relationship seen in previous research with adult populations could be extended to an adolescent population. We compared saliva cotinine concentration with plasma cotinine concentration in

heavily dependent adolescent cigarette smokers. Further, previous research on salivary flow rate and nicotine metabolism has shown variability across gender, ethnicity, and age which may impact the relationship of saliva and plasma cotinine concentrations (Berlin et al., 2007; Johnstone et al., 2006; Moolchan et al., 2006; Söderling et al., 1993; Yeh et al., 1998). Thus, we conducted a secondary analysis to examine potential differences in gender, ethnicity, and age.

Methods

Participants

Adolescent tobacco smokers were recruited through television, radio, and print advertisements as part of a three-arm, randomized, double-blind, double-dummy, placebo-controlled smoking cessation trial examining the safety, efficacy, and tolerability of two forms of NRT, nicotine patch and nicotine gum. The study was approved by the Institutional Review Board of the National Institute on Drug Abuse. All participants also received cognitive behavioral therapy. The study took place in Baltimore, MD. Eligible participants were 13–17 years of age, smoked at least ten cigarettes per day (CPD) for the last six months, and had a Fagerström Test for Nicotine Dependence (FTND, Heatherton et al., 1991) score of 5 or greater out of 10. Exclusion criteria included pregnancy, recent use of nicotine replacement therapy, untreated acute psychiatric disorder (including drug or alcohol dependence), and lack of parental permission. All participants selected for this study received a medical examination and were in good physical health. Adolescents were accompanied by their parent or guardian on the first visit and written consent for parents and assent for adolescents were obtained.

The sample consisted of 66 adolescent smokers with a mean age of 15.1 years. Girls made up 63.6% of the sample population and European Americans accounted for 66.7% of the sample. The FTND score indicated a high level of dependence, corroborated by the high number of cigarettes consumed per day. Sample demographics and smoking behaviors are provided in Table 1.

Procedures

Prior to study enrollment, information provided by participants included: demographic data, smoking trajectory, self-reported CPD, and FTND scores. Participants' height and weight were recorded at enrollment. Blood and saliva samples were taken at their first visit to determine cotinine concentrations. An experienced phlebotomist collected blood samples from the antecubital vein to a 7 mL vacutainer tube with lithium heparinate. All samples were iced immediately and centrifuged for five minutes at 3000 rpm. The plasma was then removed and frozen at -20°C until time for assay. A study nurse obtained saliva specimens by asking participants to keep a standard cotton wool dental roll in their mouth for five minutes. Participants were instructed to roll it over their tongue. The dental roll was then placed in a sterile 5 mL two-piece separating tube. All samples were centrifuged for five minutes at 3000 rpm. The top section of the separating tube that contained the dental roll was discarded and the bottom part with extract was stored in a freezer at -20°C for further analysis. Measurements of plasma and saliva nicotine, and its metabolites cotinine and 3-hydroxycotinine were performed by Labstat Inc. (Kitchner, Ontario, Canada). Nicotine and cotinine were measured according to the high resolution capillary-column gas chromatography method described in detail by Teeuwen et al. (1988) and Feyerabend & Russell (1990). Plasma and saliva 3-hydroxycotinine were measured using a capillary gas chromatography-mass spectrometry (GC-MS) method described by Jacob 3rd et al. (1992).

Data Analysis

Descriptive statistics were calculated using SPSS 13.0. Pearson correlation coefficients were used to determine the relationship between saliva and plasma levels. The ratio of saliva to plasma was computed by dividing individual saliva by individual plasma concentration. Previous research in adult populations has suggested that individual saliva-to-plasma cotinine ratios are modulated by body mass (Jarvis et al. 2003). Therefore, Pearson correlation coefficients were used to determine the relationship between saliva/plasma ratios and BMI. A partial correlation was used to control for the impact of BMI on the relationship of saliva and plasma concentrations. BMI was calculated using the standard formula: $\text{weight (lb)}/[\text{height (in)}]^2 \times 703$.

A secondary analysis was conducted to examine correlation differences across gender, ethnicity (European American, African American), and age (younger adolescents age 13–15, older adolescents age > 15). In order to control for all relevant variables a multiple regression with plasma cotinine entered as the dependent measure and saliva cotinine, gender, age, and ethnicity as well as the interactions of age X saliva cotinine, gender X saliva cotinine, and ethnicity X saliva cotinine entered as predictor variables was performed in order to determine the relationship between saliva cotinine concentrations and plasma cotinine concentrations in each of the sub-groups. Additionally, t-tests were conducted to compare the means of saliva-to-plasma ratios between each of the sub groups.

Results

Cotinine Concentrations

Figure 1 shows a scatter plot relating saliva and plasma cotinine concentration. The correlation between the two measures was high ($r = 0.84$, $p < .001$). Saliva values were on average 11.9% greater than plasma values. The mean ratio of saliva to plasma was 1.19. A significant relationship of BMI with the saliva/plasma ratio was found ($r = 0.41$, $p < .001$). However, the relationship between saliva and plasma concentration did not significantly change after controlling for BMI in a partial correlation ($r = 0.846$). Mean, median, range and quartile distribution of saliva and plasma cotinine concentrations are displayed in Table 2.

Cotinine Concentration across Gender, Ethnicity, and Age

Table 3 provides mean saliva and plasma cotinine concentration and Pearson correlations by gender, ethnicity, and age. Results of the multiple regression revealed that the predictor variables accounted for a sizable proportion of the variance of plasma cotinine $R^2 = .76$, $F(7, 62) = 24.93$, $p < .001$ (See Table 4 for unstandardized regression coefficient (B), standard error, and standardized regression coefficients (β) for all predictor variables). Of the control variables only saliva cotinine and age were significant predictors of plasma cotinine ($t = 4.77$, $p < .001$ and $t = -2.02$, $p < .05$, respectively). The interaction between age and saliva cotinine was significant ($t = 3.03$, $p < .01$) suggesting that older adolescents' saliva cotinine concentrations better predicted plasma cotinine concentrations than that of younger adolescents. The interaction between ethnicity and saliva cotinine approached significance ($t = -1.93$, $p = .058$) in the direction such that being European American appeared to be a better predictor of plasma cotinine values. The interaction between gender and saliva cotinine did not reach significance. To examine if these results were confounded by cigarettes smoked per day (CPD), CPD was entered into the model. The results of the interactions did not change. Only the control variable age was affected ($t = 1.18$, $p = .24$). No differences in saliva-to-plasma ratios were observed across sub-groups.

Discussion

This study sought to determine the degree of association between plasma and saliva cotinine concentrations in a sample of adolescent smokers. Our findings suggest that in highly-dependent adolescents, cotinine concentrations in saliva are comparable to concentrations found in plasma. This result is consistent with previous research in adult populations (Curvall et al., 1990; Jarvis et al., 2003; Rose et al., 1993). Additionally, the S/P ratio found among adolescent smokers in this study (1.19) is very comparable to that found among adult smokers (1.25) (Jarvis et al., 2003). Furthermore, our findings suggest that there is some variability in degree of correlation between saliva and plasma cotinine concentrations across age and ethnicity. Adolescents older than 15 years exhibited a closer relationship between saliva and plasma cotinine values when compared to younger adolescents. Age-related differences found here support previous findings by Jarvis et al. (2003) in which saliva-to-plasma relationships were lower in individuals under age 50 compared to their older counterparts. Our findings appear to extend these results to adolescents, showing that this relationship continues to weaken as age decreases. Additionally, the saliva-to-plasma correlation among European Americans was marginally greater than that among African Americans. The differences may be attributed to differences in smoking behavior across the different groups. Overall, these findings suggest that there may be higher variability between saliva and plasma cotinine among various sub-groups. Future research should clarify the underlying biological mechanisms of this result as well as how varying smoking behaviors might alter this relationship.

In our adolescent participants, the correlation between plasma and saliva cotinine concentrations was slightly lower than that typically found in adults. One possible explanation for this difference is that salivary glands are continuing to develop through adolescence, with the highest salivary flow rates occurring during this time and young adulthood (Söderling et al., 1993; Yeh et al., 1998). Variations across individuals in the timing of development might lead to a greater range of flow rates in adolescents than in adults. Fenoll-Palomares et al. (2004) found a significant positive correlation between salivary flow rate and pH values. Cotinine is a basic compound whose concentration in saliva is pH dependent (Cone, 1993). This relationship has not yet been assessed in the context of developmental differences in salivary flow rate, but when flow rate is increased experimentally via stimulation, cotinine concentrations decrease by 6% to 26%, presumably due to the accompanying increase in pH (Schneider et al., 1997). Variability in salivary flow rate may be greater in a given sample of adolescents than in a given sample of adults; this variability could explain the difference in our correlation between plasma and salivary levels of cotinine. We did not assess salivary pH and are thus unable to correct for it.

Despite the general association between saliva and plasma cotinine concentration, several limitations must be acknowledged when interpreting these findings. Our sample consisted of heavily dependent smokers and resulted in higher saliva and plasma concentrations than what would have been seen with a wider range of smokers. Also, in our collection of saliva specimens, cotton swabs were used as a collection device rather than a saliva stimulation device. Stimulating saliva samples might help control the salivary flow rate. Also given the recruitment and retention challenges with adolescents, some sub-groups sample sizes were small, therefore our results should be replicated with larger sample sizes that include sufficient samples of the sub-groups of interest.

To our knowledge this is the first study to examine the relationship of saliva-to-plasma cotinine concentrations in an adolescent sample. Based on our findings saliva cotinine is generally reflective of plasma cotinine concentration despite some degree of individual variation, we conclude that saliva assay is a low risk option for measuring tobacco use and exposure in adolescents. By avoiding the invasive procedure of venipuncture, researchers may be able to

reduce both practical and ethical barriers associated with youth. Future research should use a sample with a broader range of smoke intake and exposure in order to further examine the comparability of saliva and plasma cotinine concentrations across age and ethnicity among adolescents.

Acknowledgements

This research was supported by the Intramural Research Program of the NIH, National Institute on Drug Abuse. We are grateful to Elissa Thorner from the NIDA Teen Tobacco Addiction Research Treatment Clinic as well as to Dr. Stephen Heishman of NIDA-IRP for comments on previous drafts of the manuscript and technical support. We would also like to thank Dr. David Epstein and Dr. Jennifer Schroeder for assistance with statistical analyses.

References

- Benowitz NL, Jacob P 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. *Clin Pharmacol Ther* 1994;56:483–93. [PubMed: 7955812]
- Berlin I, Gasior MJ, Moolchan ET. Sex-based and hormonal contraception effects on the metabolism of nicotine among adolescent tobacco-dependent smokers. *Nicotine Tob Res* 2007;9:493–8. [PubMed: 17454704]
- Bramer SL, Kallungal BA. Clinical considerations in study designs that use cotinine as a biomarker. *Biomarkers* 2003;8:187–03. [PubMed: 12944172]
- CDC. Annual Smoking–Attributable Mortality, Years of Potential Life Lost, and Productivity Losses — United States, 1997–2001. *Morbidity and Mortality Weekly Report* 2005;54:625–8. [PubMed: 15988406]
- CDC. MMWR. 55. U.S. Department of Health and Human Services; 2006. Youth Risk Behavior Surveillance - United States, 2005. *Surveillance Summaries*; p. SS5
- Cone E. Saliva testing for drugs of abuse. Reprinted from *Saliva as a diagnostic Fluid*. *Annals of the New York Academy of Sciences* 1993;694:91–127. [PubMed: 8215090]
- Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, Enzell CR. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. *Eur J Clin Pharmacol* 1990;38:281–7. [PubMed: 2340848]
- Dolcini MM, Adler NE, Lee P, Bauman KE. An assessment of the validity of adolescent self-reported smoking using three biological indicators. *Nicotine Tob Res* 2003;5:473–83. [PubMed: 12959785]
- Eskenazi B, Prehn AW, Christianson RE. Passive and active maternal smoking as measured by serum cotinine: The effect on birthweight. *Am J Public Health* 1995;85:395–8. [PubMed: 7892926]
- Feyerabend C, Russell MA. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. *J Pharm Pharmacol* 1990;42:450–2.
- Fenoll-Palomares C, Munoz-Montagud V, Sanchiz V, Herreros B, Hernandez V, Minguez M, et al. Unstimulated salivary flow rate, pH and buffer capacity of saliva in health volunteers. *Rev Esp Enferm Dig* 2004;96:773–83. [PubMed: 15584851]
- Godtfredsen NS, Prescott E, Vestbo J, Osler M. Smoking reduction and biomarkers in two longitudinal studies. *Addiction* 2006;101:1516–22. [PubMed: 16968354]
- Hanson K, Allen S, Jensen S, Hatsukami D. Treatment of adolescent smokers with the nicotine patch. *Nicotine Tob Res* 2003;5:515–26. [PubMed: 12959789]
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. *British Journal of Addiction* 1991;86:1119–27. [PubMed: 1932883]
- Hurt RD, Croghan GA, Beede SD, Wolter TD, Croghan IT, Patten CA. Nicotine patch therapy in 101 adolescent smokers: Efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. *Arch Pediatr Adolesc Med* 2000;154:31–7. [PubMed: 10632247]
- Jacob P 3rd, Shulgin AT, Yu L, Benowitz NL. Determination of the nicotine metabolite trans-3'-hydroxycotinine in urine of smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. *J Chromatogr* 1992;583:145–54. [PubMed: 1478978]

- Jarvis MJ, Primatesta P, Erens B, Feyerabend C, Bryant A. Measuring nicotine intake in population surveys: Comparability of saliva cotinine and plasma cotinine estimates. *Nicotine Tob Res* 2003;5:349–55. [PubMed: 12791530]
- Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. *Clin Pharmacol Ther* 2006;80:319–30. [PubMed: 17015050]
- Krishnan-Sarin S, Duhig AM, McKee SA, McMahon TJ, Liss T, McFetridge A, et al. Contingency management for smoking cessation in adolescent smokers. *Exp Clin Psychopharmacol* 2006;14:306–10. [PubMed: 16893273]
- Moolchan ET, Mermelstein R. Research on tobacco use among teenagers: Ethical challenges. *J Adolesc Health* 2002;30:409–17. [PubMed: 12039510]
- Moolchan ET, Franken FH, Jaszyna-Gasior M. Adolescent nicotine metabolism: Ethnoracial differences among dependent smokers. *Ethn Dis* 2006;16:239–43. [PubMed: 16599377]
- Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. *Pediatrics* 2005;115:e407–14. [PubMed: 15805342]
- National Center for Health Statistics. *Health, United States, 2005 with Chartbook on Trends in the Health of Americans*. Hyattsville, MD: 1994.
- Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking: A review and meta-analysis. *Am J Public Health* 1994;84:1086–93. [PubMed: 8017530]
- Rose JE, Levin ED, Benowitz N. Saliva nicotine as an index of plasma levels in nicotine skin patch users. *Ther Drug Monit* 1993;15:431–35. [PubMed: 8249050]
- SAMHSA. Results from the 2004 National Survey on Drug Use and Health: (Office of Applied Studies). Rockville, Maryland: U.S. Department of Health and Human Services, NSDUH Series H-27; 2005.
- Schneider NG, Jacob P 3rd, Nilsson F, Leischow SJ, Benowitz NL, Olmstead RE. Saliva cotinine levels as a function of collection method. *Addiction* 1997;92:347–51. [PubMed: 9219396]
- Simoni M, Baldacci S, Puntoni R, Pistelli F, Farchi S, Lo Presti E, et al. Plasma, salivary and urinary cotinine in non-smoker Italian women exposed and unexposed to environmental tobacco smoking (seas study). *Clin Chem Lab Med* 2006;44:632–38. [PubMed: 16681437]
- Soderling E, Pienihakkinen K, Alanen ML, Hietaoja M, Alanen P. Salivary flow rate, buffer effect, sodium, and amylase in adolescents: A longitudinal study. *Scand J Dent Res* 1993;101:98–102. [PubMed: 7681215]
- SRNT. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res* 2002;4:149–59. [PubMed: 12028847]
- St Charles FK, Krautter GR, Dixon M, Mariner DC. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. *Psychopharmacology* 2006;189:345–54. [PubMed: 17028908]
- Stevens SL, Colwell B, Smith DW, Robinson J, McMillan C. An exploration of self-reported negative affect by adolescents as a reason for smoking: Implications for tobacco prevention and intervention programs. *Prev Med* 2005;41:589–96. [PubMed: 15917057]
- Teeuwen HW, Aalders RJ, Van Rossum JM. Simultaneous estimation of nicotine and cotinine levels in biological fluids using high-resolution capillary-column gas chromatography combined with solid phase extraction work-up. *Mol Biol Rep* 1988;13:165–75. [PubMed: 3255052]
- U.S. Department of Health and Human Services. *Preventing Tobacco Use Among Young People: A Report of the Surgeon General*. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1994.
- Yeh CK, Johnson DA, Dodds MW. Impact of aging on human salivary gland function: A community-based study. *Aging* 1998;10:421–28. [PubMed: 9932146]

Figure 1.
Scatter plot of saliva and plasma cotinine concentrations for each adolescent smoker (n =66).

Table 1

Sample Demographics and smoking behaviors of adolescent smokers (n = 66).

Baseline Measure	Sample Mean $\pm$ SD
age	15.1 $\pm$ 1.3
gender (% female)	63.60%
ethnicity (% Euro. American)	66.70%
cigarettes per day	18.3 $\pm$ 8.5
FTND Score	7.1 $\pm$ 1.3
Body Mass Index	25.2 $\pm$ 5.0

Table 2

Mean, median, range and quartile distribution of plasma and saliva cotinine concentrations in adolescent smokers (n = 66).

	Plasma (ng/mL)	Saliva (ng/mL)
mean	144.2 ± 79.2	155.9 ± 84.2
median	135.9	146.3
range	6.2 – 355.7	3.7 – 434.8
quartiles		
25%	80.1	100.4
50%	135.9	146.3
75%	201.5	193.5

Table 3
Means and standard deviations for saliva and plasma concentrations by gender, ethnicity, and age in adolescent smokers (n = 66).

	n	mean age	saliva (ng/mL)	Plasma (ng/mL)	Pearson's r	S/P ratio
gender						
boys	24	15.33	166.55 ± 74.82	152.65 ± 84.11	0.727	1.27
girls	42	15.02	149.95 ± 89.41	139.31 ± 76.91	0.899	1.15
ethnicity						
Euro. American	44	15.14	151.86 ± 76.85	143.79 ± 75.30	0.903	1.13
Af. American	19	15.32	170.48 ± 102.92	148.65 ± 92.73	0.737	1.36
age						
13 – 15	38	14.21	143.05 ± 85.09	126.97 ± 70.88	0.744	1.26
>15	28	16.39	173.55 ± 81.14	167.50 ± 85.11	0.944	1.10

Table 4

Predictors of plasma cotinine concentrations in adolescent smokers (n = 66).

Variable	B	SE B	β
saliva cotinine	0.64	0.13	0.68 [*]
gender	-13.92	26.81	-0.08
age	-49.19	24.33	-0.31 ^{***}
ethnicity	37.04	25.11	0.21
ageXsaliva cotinine	0.40	0.13	0.51 ^{**}
genderXsaliva cotinine	0.12	0.15	0.15
ethnicityXsaliva cotinine	-0.27	0.14	-0.32

 $R^2 = .76,$ ^{*}
 $p < .001,$ ^{**}
 $p < .01,$ ^{***}
 $p < .05$